00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in...
18:39 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Glenmark reports Phase IIa data for anti-OX40 mAb in atopic dermatitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a placebo-controlled Phase IIa trial in over 60 patients with moderate to severe atopic dermatitis showing that GBR 830 reduced mRNA biomarkers of disease activity, including S100...
21:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg oral laquinimod (SAIK-MS) missed the primary endpoint of reducing brain atrophy on MRI as measured by percent brain volume change from baseline to week 48 compared to...
18:52 , Oct 5, 2017 |  BC Innovations  |  Translation in Brief

SSRIs' first responders

Researchers at The Rockefeller University have identified a role for CCK-expressing neurons in initiating responses to SSRIs for depression and manipulated the neurons to recapitulate the drugs' effects. The findings could lead to faster-acting antidepressants...
13:36 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other molecule...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting S100A4 or depleting S100A4-expressing cells could help treat glioblastoma multiforme (GBM) and other gliomas. In samples from glioma patients, high tumor levels of S100A4...
17:44 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Arrhythmia In vitro, cell culture and mouse studies suggest promoting phosphorylation of HRC at Ser96 could help treat arrhythmia. In an HRC-knockout mouse cardiomyocyte model of isoproterenol-induced arrhythmia, an adenoviral vector encoding HRC-S96D, which mimics...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
21:05 , Jul 18, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of S100A10, S100A11 and TNC mRNAs could help predict survival in lung cancer. In 57 lung adenocarcinoma patients, mRNA levels of S100A10, S100A11 and TNC were higher in tumors than in...
15:58 , Jun 7, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Atherosclerosis; hematology Patient sample and mouse studies suggest inhibiting S100A9 could help treat diabetes-related atherosclerosis and thrombocytosis. In plasma samples from Type II diabetes patients, levels of S100A9 were higher than in samples from healthy...